ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

Senate Committee To Debate Budget Bill Sept. 10; Increase Expected For Breast Cancer Research

September 4, 1992

National Cancer Act: Early Promises Were Overstated

May 15, 1998

In Brief: DCE Board Nixes NIH Intramural Postdoctural Program Magazines Rapped For Cigarette Ads

July 13, 1984

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

January 25, 2002

In Congress: $135 Million Expected For DOD Breast Cancer Research Program

July 24, 1998

Chabner Cautions Against Downsizing, Consolidation Of NCI Intramural Programs

March 3, 1995